Marzo-Ortega Helena, Green Michael J, Keenan Anne-Maree, Wakefield Richard J, Proudman Susanna, Emery Paul
Chapel Allerton Hospital, Leeds, UK.
Arthritis Rheum. 2007 Feb 15;57(1):154-60. doi: 10.1002/art.22467.
To determine the outcome after 52 weeks of early intervention with intraarticular corticosteroid injections followed by sulfasalazine versus conservative therapy in patients with recent-onset oligoarthritis in a randomized controlled trial.
Patients with <or=4 joints with clinical synovitis (disease duration <or=12 months) were randomized to early intervention (EI) with intraarticular methylprednisolone into all synovitic joints or to conservative treatment (CT) with nonsteroidal antiinflammatory drugs alone. Sulfasalazine was administered in both groups for persistent disease or disease that evolved into a polyarthritis. Primary outcome was complete response (CR) defined as the absence of synovitis at 52 weeks. Secondary outcomes included CR at weeks 4 and 12, function (Health Assessment Questionnaire), pain (0-100-mm visual analog scale), and work status.
Fifty-nine patients (34 men, 25 women; mean age 32.9 years; median early morning stiffness 30 minutes) were randomized. At baseline, two-thirds reported that they were work impaired. At 52 weeks, 81% of patients in the EI group achieved CR compared with 57% in the CT group (chi(2) = 3.833, 1 df, P = 0.05). In addition, 45% of patients in the EI group received sulfasalazine as opposed to 14% in the CT group (chi(2) = 5.156, 1 df, P = 0.019). There were no differences in physical disability or work impairment between the treatment groups.
Oligoarthritis has a significant impact on function and work ability. Patients treated with EI using intraarticular corticosteroids followed by sulfasalazine therapy if resistant demonstrated reduced synovitis 12 months after treatment compared with those initially treated with more conservative therapy.
在一项随机对照试验中,确定近期发病的少关节炎患者在接受关节内注射皮质类固醇随后使用柳氮磺胺吡啶进行早期干预52周后的疗效,并与保守治疗进行比较。
临床滑膜炎累及关节≤4个(病程≤12个月)的患者被随机分为两组,一组接受早期干预(EI),即向所有滑膜炎关节内注射甲基强的松龙,另一组接受保守治疗(CT),即仅使用非甾体抗炎药。两组中持续性疾病或发展为多关节炎的患者均给予柳氮磺胺吡啶治疗。主要结局为完全缓解(CR),定义为52周时无滑膜炎。次要结局包括第4周和第12周时的CR、功能(健康评估问卷)、疼痛(0 - 100毫米视觉模拟量表)和工作状态。
59例患者(34例男性,25例女性;平均年龄32.9岁;晨间僵硬中位数30分钟)被随机分组。基线时,三分之二的患者报告其工作受到影响。52周时,EI组81%的患者达到CR,而CT组为57%(χ² = 3.833,自由度1,P = 0.05)。此外,EI组45%的患者接受了柳氮磺胺吡啶治疗,而CT组为14%(χ² = 5.156,自由度1,P = 0.019)。治疗组之间在身体残疾或工作受损方面无差异。
少关节炎对功能和工作能力有显著影响。与最初接受更保守治疗的患者相比,采用关节内注射皮质类固醇进行早期干预并在耐药时使用柳氮磺胺吡啶治疗的患者在治疗12个月后滑膜炎减轻。